Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04821778

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Cohort Study of Definitive Chemoradiotherapy for Esophageal or Esophagogastric Junction Cancer

Status
Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
2,000 (estimated)
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.

Conditions

Interventions

TypeNameDescription
RADIATIONRadiotherapy50-66Gy/1.8-2.2Gy/25-30f
DRUGPlatinum based chemotherapyq1-3W according to physician's preference
DRUGPaclitaxel based chemotherapyq1-3W according to physician's preference
DRUGImmunotherapyAnti-PD-1/PD-L1 Antibody
DRUG5-FU Analog based chemotherapyW1-5 qW or d1-14, q3W according to physician's preference
DRUGNimotuzumab200-400mg, d1,qW

Timeline

Start date
2002-01-01
Primary completion
2030-12-31
Completion
2030-12-31
First posted
2021-03-30
Last updated
2026-01-21

Locations

5 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04821778. Inclusion in this directory is not an endorsement.